- The combined company has released more than 150 GMP batches and is supporting 10 IND filings this year
- Kincellis operates 16 qualified GMP manufacturing suites across its three-site network, backed by more than 200 employees
- Debt financing for the transaction was provided by JP Morgan alongside the equity investment
NewSpring Capital led the undisclosed equity financing behind the merger of Kincell Bio and Cellipont Bioservices, forming Kincellis Advanced Therapies, a US-based contract development and manufacturing organization focused on cell therapies and other advanced modalities.
Existing investors Kineticos Life Sciences, HealthQuest Capital and Great Point Partners also supported the equity financing, alongside a debt facility provided by JP Morgan.
Kincellis combines Kincell’s immune-cell technology expertise with Cellipont’s experience across stem cells, iPSCs, MSCs, dendritic cells, exosomes and emerging mRNA-enabled approaches, allowing the combined company to support autologous and allogeneic therapies across a broad range of cell types and modalities, from early development through commercial supply. Together, the two companies have released more than 150 GMP batches for clients and are supporting 10 IND filings this year.
The combined company operates approximately 140,000 square feet of development and manufacturing infrastructure across Gainesville, Florida; Research Triangle Park, North Carolina; and The Woodlands, Texas, spanning 16 operational, qualified GMP manufacturing suites. The operations team, drawn from both organizations, comprises more than 200 team members.
William Blair & Company served as financial advisor to Cellipont Bioservices on the transaction. Financial terms were not disclosed.
Editor’s note: This news brief was produced with the assistance of artificial intelligence.